Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389

计划入组 34 人 · 首次发布于 2020 年 3 月 26 日

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

计划入组 320 人 · 首次发布于 2021 年 12 月 20 日

Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses

计划入组 19 人 · 首次发布于 2012 年 11 月 26 日

Biofor-389

LAF-389

GS-389

NEODYNE BIOSCIENCES, INC.

United States

Context Therapeutics

United States

Scholar Rock, Inc.

United States

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Ona Therapeutics Appoints ADC Development Veteran Dr. Antoine Yver as Board Chair to Advance Breast Cancer Pipeline

REVEAL GENOMICS and Ona Therapeutics Partner to Advance Novel ADC Cancer Treatment with Biomarker Strategy